403 related articles for article (PubMed ID: 35660139)
21. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ
Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197
[TBL] [Abstract][Full Text] [Related]
22. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
23. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
[TBL] [Abstract][Full Text] [Related]
24. Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry.
Vincenzi B; Cortellini A; Mazzocca A; Orlando S; Romandini D; Aguilar-Company J; Ruiz-Camps I; Valverde Morales C; Eremiev-Eremiev S; Tondini C; Brunet J; Bertulli R; Provenzano S; Bower M; Generali D; Salazar R; Sureda A; Prat A; Vasiliki M; Van Hemelrijck M; Sita-Lumsden A; Bertuzzi A; Rossi S; Jackson A; Grosso F; Lee AJX; Murphy C; Belessiotis K; Mukherjee U; Pommeret F; Loizidou A; Gaidano G; Dettorre GM; Grisanti S; Tucci M; Fulgenzi CAM; Gennari A; Napolitano A; Pinato DJ
Ther Adv Med Oncol; 2024; 16():17588359231225028. PubMed ID: 38249336
[TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
26. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.
; Thompson MG; Yoon SK; Naleway AL; Meece J; Fabrizio TP; Caban-Martinez AJ; Burgess JL; Gaglani M; Olsho LEW; Bateman A; Lundgren J; Grant L; Phillips AL; Groom HC; Stefanski E; Solle NS; Ellingson K; Lutrick K; Dunnigan K; Wesley MG; Guenther K; Hunt A; Mak J; Hegmann KT; Kuntz JL; Bissonnette A; Hollister J; Rose S; Morrill TC; Respet K; Fowlkes AL; Thiese MS; Rivers P; Herring MK; Odean MJ; Yoo YM; Brunner M; Bedrick EJ; Fleary DE; Jones JT; Praggastis J; Romine J; Dickerson M; Khan SM; Lamberte JM; Beitel S; Webby RJ; Tyner HL
JAMA; 2022 Oct; 328(15):1523-1533. PubMed ID: 36255426
[TBL] [Abstract][Full Text] [Related]
27. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
[TBL] [Abstract][Full Text] [Related]
29. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
30. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
Menni C; Valdes AM; Polidori L; Antonelli M; Penamakuri S; Nogal A; Louca P; May A; Figueiredo JC; Hu C; Molteni E; Canas L; Österdahl MF; Modat M; Sudre CH; Fox B; Hammers A; Wolf J; Capdevila J; Chan AT; David SP; Steves CJ; Ourselin S; Spector TD
Lancet; 2022 Apr; 399(10335):1618-1624. PubMed ID: 35397851
[TBL] [Abstract][Full Text] [Related]
31. Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer.
Cortellini A; Aguilar-Company J; Salazar R; Bower M; Sita-Lumsden A; Plaja A; Lee AJX; Bertuzzi A; Tondini C; Diamantis N; Martinez-Vila C; Prat A; Apthorp E; Gennari A; Pinato DJ
Br J Cancer; 2022 Nov; 127(10):1787-1792. PubMed ID: 35995934
[TBL] [Abstract][Full Text] [Related]
32. Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study.
Schmidt M; Hajage D; Landoll M; Pequignot B; Langouet E; Amalric M; Mekontso-Dessap A; Chiscano-Camon L; Surman K; Finnerty D; Santa-Teresa P; Arcadipane A; Millán P; Roncon-Albuquerque R; Blandino-Ortiz A; Blanco-Schweizer P; Ricart P; Gimeno-Costa R; Albacete CL; Fortuna P; Schellongowski P; Dauwe D; Winiszewski H; Kimmoun A; Levy B; Hermans G; Grasselli G; Lebreton G; Guervilly C; Martucci G; Karagiannidis C; Riera J; Combes A;
Lancet Respir Med; 2023 Feb; 11(2):163-175. PubMed ID: 36640786
[TBL] [Abstract][Full Text] [Related]
33. Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.
Grasselli G; Zanella A; Carlesso E; Florio G; Canakoglu A; Bellani G; Bottino N; Cabrini L; Castelli GP; Catena E; Cecconi M; Cereda D; Chiumello D; Forastieri A; Foti G; Gemma M; Giudici R; Grazioli L; Lombardo A; Lorini FL; Madotto F; Mantovani A; Mistraletti G; Mojoli F; Mongodi S; Monti G; Muttini S; Piva S; Protti A; Rasulo F; Scandroglio AM; Severgnini P; Storti E; Fumagalli R; Pesenti A;
JAMA Netw Open; 2022 Oct; 5(10):e2238871. PubMed ID: 36301541
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Dayan GH; Rouphael N; Walsh SR; Chen A; Grunenberg N; Allen M; Antony J; Asante KP; Bhate AS; Beresnev T; Bonaparte MI; Celle M; Ceregido MA; Corey L; Dobrianskyi D; Fu B; Grillet MH; Keshtkar-Jahromi M; Juraska M; Kee JJ; Kibuuka H; Koutsoukos M; Masotti R; Michael NL; Neuzil KM; Reynales H; Robb ML; Villagómez Martínez SM; Sawe F; Schuerman L; Tong T; Treanor J; Wartel TA; Diazgranados CA; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
Lancet Respir Med; 2023 Nov; 11(11):975-990. PubMed ID: 37716365
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
[TBL] [Abstract][Full Text] [Related]
36. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study.
Pinato DJ; Scotti L; Gennari A; Colomba-Blameble E; Dolly S; Loizidou A; Chester J; Mukherjee U; Zambelli A; Aguilar-Company J; Bower M; Galazi M; Salazar R; Bertuzzi A; Brunet J; Mesia R; Sita-Lumsden A; Colomba J; Pommeret F; Seguí E; Biello F; Generali D; Grisanti S; Rizzo G; Libertini M; Moss C; Evans JS; Russell B; Wuerstlein R; Vincenzi B; Bertulli R; Ottaviani D; Liñan R; Marrari A; Carmona-García MC; Sng CCT; Tondini C; Mirallas O; Tovazzi V; Fotia V; Cruz CA; Saoudi-Gonzalez N; Felip E; R Lloveras A; Lee AJX; Newsom-Davis T; Sharkey R; Chung C; García-Illescas D; Reyes R; Sophia Wong YN; Ferrante D; Marco-Hernández J; Ruiz-Camps I; Gaidano G; Patriarca A; Sureda A; Martinez-Vila C; Sanchez de Torre A; Rimassa L; Chiudinelli L; Franchi M; Krengli M; Santoro A; Prat A; Tabernero J; V Hemelrijck M; Diamantis N; Cortellini A;
Eur J Cancer; 2021 Jun; 150():190-202. PubMed ID: 33932726
[TBL] [Abstract][Full Text] [Related]
37. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021.
Johnson AG; Amin AB; Ali AR; Hoots B; Cadwell BL; Arora S; Avoundjian T; Awofeso AO; Barnes J; Bayoumi NS; Busen K; Chang C; Cima M; Crockett M; Cronquist A; Davidson S; Davis E; Delgadillo J; Dorabawila V; Drenzek C; Eisenstein L; Fast HE; Gent A; Hand J; Hoefer D; Holtzman C; Jara A; Jones A; Kamal-Ahmed I; Kangas S; Kanishka F; Kaur R; Khan S; King J; Kirkendall S; Klioueva A; Kocharian A; Kwon FY; Logan J; Lyons BC; Lyons S; May A; McCormick D; ; Mendoza E; Milroy L; O'Donnell A; Pike M; Pogosjans S; Saupe A; Sell J; Smith E; Sosin DM; Stanislawski E; Steele MK; Stephenson M; Stout A; Strand K; Tilakaratne BP; Turner K; Vest H; Warner S; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):132-138. PubMed ID: 35085223
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A; Dettorre GM; Dafni U; Aguilar-Company J; Castelo-Branco L; Lambertini M; Gennatas S; Angelis V; Sita-Lumsden A; Rogado J; Pedrazzoli P; Viñal D; Prat A; Rossi M; Berardi R; Alonso-Gordoa T; Grisanti S; Dimopoulou G; Queirolo P; Pradervand S; Bertuzzi A; Bower M; Arnold D; Salazar R; Tucci M; Harrington KJ; Mazzoni F; Mukherjee U; Tsourti Z; Michielin O; Pommeret F; Brunet J; Vincenzi B; Tonini G; Patriarca A; Biello F; Krengli M; Tabernero J; Pentheroudakis G; Gennari A; Peters S; Romano E; Pinato DJ
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450384
[TBL] [Abstract][Full Text] [Related]
40. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
